Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 28;15(3):309.
doi: 10.3390/diagnostics15030309.

Effect of Hyaluronic Acid Compared to Platelet-Rich Plasma as Adjuvants to Bone Marrow Mesenchymal Stem Cell Treatment of Knee Osteoarthritis: Analysis from Two Clinical Trials

José María Lamo-Espinosa  1   2 , Álvaro Suárez-López Del Amo  1 , Jorge María Núñez-Córdoba  3   4 , Juan F Blanco  5 , Mikel Sánchez  6   7 , Victoria Moreno  1 , Marta Cabrera  1 , Froilán Granero-Moltó  2 , Emma Muiños  2 , Manuel M Mazo  2 , Íñigo Crespo-Cullell  5 , Gonzalo Mora  1 , Diego Delgado  6   7 , Orlando Pompei-Fernández  6 , Jesús Dámaso Aquerreta  8 , María Vitoria Sola  1 , Andrés Valentí-Azcárate  1 , Enrique J Andreu  2 , Miriam López-Parra  9 , Eva M Villarón  9 , Juan Ramón Valentí-Nin  1 , Fermín Sánchez-Guijo  9 , Felipe Prósper  2   10
Affiliations

Effect of Hyaluronic Acid Compared to Platelet-Rich Plasma as Adjuvants to Bone Marrow Mesenchymal Stem Cell Treatment of Knee Osteoarthritis: Analysis from Two Clinical Trials

José María Lamo-Espinosa et al. Diagnostics (Basel). .

Abstract

Background: Bone marrow mesenchymal stem cell (BM-MSC) therapy has emerged as a safe and feasible treatment option for patients with knee osteoarthritis (OA). However, the role of adjuvants remains unclear. Our aim was to evaluate the clinical and radiological effects of hyaluronic acid (HA) in comparison to platelet-rich plasma (PRP) as adjuvants to 100 × 106 BM-MSCs in the treatment of knee OA. Methods: We used data from two randomized, parallel-group and controlled clinical trials which tested the efficacy of BM-MSC, previously published in 2016 (Clinical Trials.gov identifier NCT02123368, Nº EudraCT: 2009-017624-72) and 2020 (Clinical Trials.gov identifier NCT02365142. Nº EudraCT: 2011-006036-23). Results: Of the 34 patients included in the study, 24 had received 100 × 106 BM-MSCs plus PRP and 10 had received 100 × 106 BM-MSCs plus HA. On average, BM-MSC plus HA showed a higher improvement in VAS for pain [β-coefficient: -1.25; 95% confidence interval (95% CI):-2.20 to -0.30) than BM-MSC plus PRP (p = 0.01). We also observed that BM-MSC plus HA showed a greater improvement in all the WOMAC subscales scores and in the WOMAC overall score, compared to BM-MSC plus PRP, although these differences were not statistically significant. The Whole-Organ Magnetic Resonance Imaging Score (WORMS) at 12 months was more beneficial with 100 × 106 BM-MSCs plus HA (β-coefficient: -12.61; 95% CI: -19.71, -5.52) than with BM-MSC plus PRP (p = 0.001). Conclusions: The clinical and radiological outcomes after BM-MSC therapy for knee OA could differ according to the adjuvant employed. HA showed greater clinical effectiveness and fewer instances of articular degeneration than PRP as an adjuvant.

Keywords: cell therapy; hyaluronic acid; mesenchymal stem cells; osteoarthritis; platelet-rich plasma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Visual analog scale (VAS) for pain over time according to coadjuvant. HA—hyaluronic acid. PRP—platelet-rich plasma.
See this image and copyright information in PMC

References

    1. Al-Najar M., Khalil H., Al-Ajlouni J., Al-Antary E., Hamdan M., Rahmeh R., Alhattab D., Samara O., Yasin M., Abdullah A.A., et al. Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: A phase I/II study. J. Orthop. Surg. Res. 2017;12:1–6. doi: 10.1186/s13018-017-0689-6. - DOI - PMC - PubMed
    1. Bastos R., Mathias M., Andrade R., Amaral R.J.F.C., Schott V., Balduino A., Bastos R., Miguel Oliveira J., Reis R.L., Rodeo S., et al. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: A controlled, double-blind clinical trial. Knee Surg. Sports Traumatol. Arthrosc. 2019;28:1989–1999. doi: 10.1007/s00167-019-05732-8. - DOI - PubMed
    1. Lamo-Espinosa J.M., Mora G., Blanco J.F., Granero-Moltó F., Nuñez-Córdoba J.M., Sánchez-Echenique C., Bondía J.M., Aquerreta J.D., Andreu E.J., Ornilla E., et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase I/II) J. Transl. Med. 2016;14:246. doi: 10.1186/s12967-016-0998-2. - DOI - PMC - PubMed
    1. Orozco L., Munar A., Soler R., Alberca M., Soler F., Huguet M., Sentís J., Sánchez A., García-Sancho J. Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells. Transplantation. 2014;97:e66–e68. doi: 10.1097/TP.0000000000000167. - DOI - PubMed
    1. Lamo-Espinosa J.M., Blanco J.F., Sánchez M., Moreno V., Granero-Moltó F., Sánchez-Guijo F., Crespo-Cullel Í., Mora G., San Vicente D.D., Pompei-Fernández O., et al. Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis. J. Transl. Med. 2020;18:1–9. doi: 10.1186/s12967-020-02530-6. - DOI - PMC - PubMed

LinkOut - more resources